Adicet Bio, Inc.
ACET
Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and enhance persistence for durable activity inā¦ read more
Healthcare
Biotechnology
8 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$9.47
Price+3.90%
$0.36
1Y
Price
Market Cap
$88.481m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow Margin-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow MarginRevenue
$0.00
-
1y CAGR-
3y CAGR-25.0%
5y CAGREarnings
-$108.833m
+6.8%
1y CAGR+8.3%
3y CAGR-19.9%
5y CAGREPS
-$14.90
+12.1%
1y CAGR+30.8%
3y CAGR-0.6%
5y CAGRBook Value
$140.065m
$169.382m
Assets$29.317m
Liabilities$13.898m
DebtDebt to Assets
8.2%
-0.1x
Debt to EBITDAFree Cash Flow
-$91.622m
+5.5%
1y CAGR+2.2%
3y CAGR-13.2%
5y CAGRNo items found.
Press Releases
Statements and updates from the company